Ocular Therapeutix Provides First Quarter 2023 Financial Results and Corporate Update
08.05.2023 - 12-month Top-Line Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD to be Presented in June at the Clinical Trials at the Summit 2023 Meeting Presented Pre-Clinical and Clinical ...
Source: wallstreet-online.de